贝伐珠单抗相关胃肠道穿孔:FAERS数据库回顾
基于FAERS数据库2004年至2021年报告,共识别2874例贝伐珠单抗相关胃肠道穿孔,其中1375例资料完整。最常见穿孔部位为大 intestine(55.2%),最常见适应证为结直肠癌(50.3%),死亡报告占40.3%。
要点
- 贝伐珠单抗相关胃肠道穿孔多发生于大 intestine,结直肠癌患者最常见。
- 穿孔后死亡报告率高,达40.3%,需警惕致命风险。
- 罕见胃食管穿孔亚组被描述,既往缺乏数据。
核心结论
- 贝伐珠单抗相关胃肠道穿孔是常致命的并发症,大 intestine 穿孔最常见,胃食管穿孔罕见但存在。
主要发现
- 患者平均年龄61.9±11.4岁;698例有穿孔部位描述,其中大 intestine 385例(55.2%)。
- 最常见适应证为结直肠癌691例(50.3%),卵巢癌197例(14.3%),非小细胞肺癌182例(13.2%)。
临床怎么用
- 临床使用贝伐珠单抗时应警惕胃肠道穿孔风险,尤其结直肠癌患者,出现相关症状需及时评估。
局限性
- 基于自发报告数据库,可能存在报告偏倚和资料不完整,无法计算确切发生率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bevacizumab is used in the treatment of advanced malignancies and has a "black box" warning for gastrointestinal perforations. Despite this known side effect, there are no large descriptive series of patients who experience bevacizumab-induced gastrointestinal perforations. AIM: To review and describe post-market cases of bevacizumab-induced gastrointestinal perforation reported by healthcare professionals to the United States Food and Drug Association Adverse Event Reporting System (FAERS) database. METHODS: In total, 74 025 cases of bevacizumab-induced adverse drug reaction were reported to FAERS from January 1 2004 to July 6 2021. We identified 2874 cases of bevacizumab-induced gastrointestinal perforation. A total of 1375 cases were determined to contain complete patient demographic data after the removal of duplicates and were reviewed. Subgroup analysis was completed on gastro-oesophageal perforations given the lack of prior data. RESULTS: The average patient age was 61.9 ± 11.4 years. A total of 698 cases included descriptive locations of perforations with most occurring in the large intestine (385 cases, 55.2% of specifically described cases). Colorectal cancer was the most common indication for bevacizumab (691 cases, 50.3%) followed by ovarian cancer (197 cases, 14.3%) and non-small cell lung cancer (182 cases, 13.2%). Death was reported in 554 patients (40.3% of cases). Sixty-two cases of gastro-oesophageal perforation were identified. CONCLUSIONS: This is the largest collective descriptive study of bevacizumab-induced gastrointestinal perforations, and sheds light on this often fatal complication. We additionally identified and described a rare subgroup of patients experiencing bevacizumab-induced gastro-oesophageal perforation not previously described.
引用
- Wichelmann TA, Abdulmujeeb S, Ehrenpreis ED, et al. Bevacizumab and gastrointestinal perforations: a review from the FDA Adverse Event Reporting System (FAERS) database. Aliment Pharmacol Ther. 2021. PMID: 34499740. doi:10.1111/apt.16601
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。